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Although it is well established that regardless of the host, the
route of administration, or the speciation, aluminium (Al) is a
potent neurotoxicant [52,72-74,85], the basis for its toxicity
is still unkown. Aluminium has been found to be a major
causative factor in the development of dialysis en-
cephalopathy [5]. High concentrations of Al are reported in
plasma and tissue samples of dialyzed and nondialyzed pa-
tients with chronic renal failure [3,5,55]. The toxicity of Al
also includes osteomalacia and anemia [34]. In recent
years, numerous investigations have also demonstrated that
Al disrupts a wide variety of neurological processes.
Moreover, Al has been proposed as a contributor to the
pathogenesis of serious neurological disorders such as
Alzheimer’s disease (AD), amyotrophic lateral sclerosis and
parkinsonism-dementia of Guam [59,66,77]. The pathologic
features that these neurodegenerative diseases share in-
clude abnormal phosphorylation of neuronal cytoskeletal
proteins and the abnormal deposition of these proteins in
neurons. In susceptible species, Al induces cytoskeletal
changes in which neurofilaments accumulate in neuronal
cell bodies and proximal axonal enlargement [63,76]. Al-
though Al has been reported to impact on gene expression,
this does not appear to be critical to the induction of cy-
toskeletal pathology [74].
In any case, while there is unequivocal evidence that Al is
a potent neurotoxic agent inducing neurofibrillary degenera-
tion in animal brains after intracerebral Al injections and sys-
temic Al exposure [72-75], the association between Al expo-
sure and the pathogenesis of AD and related disorders
remains unproven and questionable [23,33,50,70]. Howev-
er, a number of reports in the recent literature strongly sug-
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Abstract
It is well known that aluminium is potentially neurotoxic.
Moreover, there has been concern in recent years that di-
etary and environmental exposure to aluminium might cause
developmental toxicity in mammals. While it is well estab-
lished that aluminium may be a developmental toxic when
administered parenterally, until recently there was little con-
cern about embryo/fetal consequences of aluminium inges-
tion because bioavailability was considered low. This paper
summarizes the results of recent investigations on the em-
bryo/fetal toxicity of aluminium, the potential reproductive
toxicology of aluminium, and the neurodevelopmental and
behavioural effects deriving from aluminium exposure dur-
ing pregnancy. Potential therapies to protect against alu-
minium-induced developmental toxicity are also reviewed.
Resum
És ben conegut que l’alumini és potencialment neurotòxic.
En els darrers anys s’ha plantejat si l’exposició dietètica i
mediambiental a l’alumini podia causar toxicitat en el desen-
volupament dels mamífers. Mentre que està ben establert
que l’alumini pot ser un tòxic per al desenvolupament quan
s’administra parenteralment, fins fa poc no hi havia gaire in-
quietud per les conseqüències embrio/fetals derivades de
la ingesta d’alumini, ja que la seva biodisponibilitat era con-
siderada baixa. Aquest article resumeix els resultats obtin-
guts en investigacions recents sobre la toxicitat embrio/fetal
de l’alumini, la potencial toxicologia reproductiva d’aquest
element, així com els efectes sobre el neurodesenvolupa-
ment i el comportament derivats de l’exposició a l’alumini
durant la gestació. Finalment, també es revisen les teràpies
potencials per protegir-se de la toxicitat causada per l’alu-
mini en el desenvolupament.
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gest that, by limiting human exposure to unnecessarily high
Al concentrations, the incidence of AD might be reduced
[53,58,60].
With respect to potential Al toxicity, until recently, there
was relatively little concern about toxic consequences of Al
ingestion because it was assumed that Al was not orally
bioavailable. However, in recent years, it has been shown
that although the gastrointestinal tract normally represents a
major barrier to Al absorption, under some circumstances
this barrier can be breached [3,4]. Consequently, individu-
als ingesting large amounts of Al compounds do absorb a
definite amount of Al [3]. Aluminium absorption, excretion,
tissue retention, and deposition all depend on the properties
of the Al3+ complexes formed with biological ligands. The
complexity in the aqueous chemistry of Al has also affected
Al toxicity studies [54].
Normally, mammals maintain very low Al concentrations
in their tissues because of a combination of low intestinal up-
take and rapid clearance. However, it is now recognized that
toxicity can occur either if absorption is markedly increased
or renal clearance is impaired. Although most foods contain
small but variable amounts of Al, the exposure to Al through
the diet is small compared to the quantities of Al in many
antacid products, some buffered analgesics and other ther-
apeutic preparations [24]. Some people consume as much
as an additional 5 g of Al daily from these compounds
[51,56].
Aluminium-containing antacids are widely used nonpre-
scription medications, which have been administered for
many years for the treatment of various gastrointestinal dis-
orders. During pregnancy, dyspepsia is a common com-
plaint and antacids are widely used to reduce the dyspeptic
symptoms. In most of these drugs, Al is present as Al hy-
droxide, which has a very low aqueous solubility. However,
the consumption of high amounts of Al compounds during
pregnancy can mean a potential risk of Al accumulation be-
cause of the relatively great number of dietary constituents
(ascorbate, citrate, lactate, succinate, etc.), which can en-
hance the gastrointestinal Al absorption [28,29,31].
Until recently, information on human studies to determine
whether Al ingestion could have adverse effects on the out-
come of pregnancies was very scarce. In 1986, Weberg et
al. [78] reported that since it was not clear whether maternal
Al could increase the Al levels in the fetus, high-dose
antacids should not be consumed during pregnancy. More
recently, Golding et al. [36] carried out studies to determine
whether Al sulfate accidentally added to a local water supply
(Cornwall, United Kingdom) had adverse embyo/fetal ef-
fects in pregnant women. It was concluded that although a
lack of major problems associated with fetal exposure to
high Al doses was noted, the relatively small number of
pregnancies made it impossible to say that high doses of Al
sulfate would be safe during gestation. On the other hand,
the literature contains little information regarding either the
experimental embryotoxic and teratogenic potential of Al, or
the effects of gestational exposure to Al on the fetus and
newborn. In order to obtain an overall understanding of the
reproductive and developmental toxicity of Al, an extensive
research program on these topics was initiated in our labo-
ratory in the mid-1980s. Data about Al-induced embryo/fetal
toxicity, the potential reproductive toxicology and the post-
natal effects of Al are here reviewed with special attention to
our results.
Embryo/fetal toxicity of aluminium
It is now well established that Al may be an embryo/fetal tox-
in depending on the route of exposure and/or the solubility of
the Al compound administered. While Al chloride was found
to be embryotoxic and teratogenic when given parenterally
to rats and mice [8,18,20,79], no evidence of maternal and
embryo/fetal toxicity was observed when high doses of Al
hydroxide were given to pregnant rats and mice. Thus, no
developmental effects of Al hydroxide were observed when
Al hydroxide was given orally to rats at 66.5, 133, and 266
mg Al/kg/day [44] or mice at 23, 46, and 92 mg Al/kg/day
[27] during organogenesis. In addition, the maternal-pla-
cental Al concentrations were not significantly different be-
tween control and Al-treated rats, while Al could not be de-
tected in the whole fetuses in any of the groups [44]. These
results indicate that Al from Al hydroxide is very poorly ab-
sorbed and does not reach the fetus at levels, which might
mean a developmental hazard. In mice, for example, the
doses of Al hydroxide would be equivalent to those con-
sumed by people of 60 kg body weight who ingest 1.4, 2.8
or 5.5 g of Al per day, respectively, which are much higher
than the amounts usually ingested for peptic disorders.
In contrast to this, in a previous study oral administration
of Al nitrate nonahydrate (13, 26 and 62 mg Al/kg/day) to
pregnant rats on gestation days 6-14 resulted in decreased
fetal body weight and increased the incidence and types of
external, visceral, and skeletal malformations and variations
in all the Al-treated groups [65]. It was concluded that al-
though embryolethality was not induced in rats by oral Al ad-
ministration, teratogenic effects might result at Al nitrate dos-
es as high as those administered in that study,
corresponding approximately to 1/20, 1/10, and 1/5 of the
acute oral LD50 of Al nitrate nonahydrate for adult female rats
[57]. These data together with those obtained from studies in
which Al hydroxide was given orally to rats and mice [27,44]
show that Al compound solubility plays an essential role in
the potential embryo/fetal toxicity of Al.
In recent years, it has been demonstrated that ingestion
of Al hydroxide concurrently with fruit juices or with some
common organic constituents of the diet (citrate, ascorbate,
lactate, succinate, etc.) causes a marked increase in the
gastrointestinal absorption of Al in healthy individuals [28-
31,69]. The presence of Al complexing compounds in the
gastrointestinal tract with gastric acid solubilizes Al cations
and may thus result in the equilibrium formation of a soluble
complex of Al, which by preventing reprecipitation, may re-
sult in Al absoprtion [64]. Taking this into account, we inves-
tigated whether the concurrent ingestion of citric, lactic or
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ascorbic acid and high doses of Al hydroxide might result in
developmental toxicity in mammals.
The concurrent oral administration of citric acid (62
mg/kg/day) and Al hydroxide (133 mg Al/kg/day) to rats on
gestation days 6-15 did not modify the lack of embryotoxici-
ty and teratogenicity previously reported. However, the inci-
dence of skeletal variations (delayed ossification of occipital
and sternebrae) was significantly increased [45]. Although
not significantly different, the incidence of skeletal variations
also increased in fetuses of pregnant mice given oral doses
of Al hydroxide (57 mg Al/kg/day) and lactic acid (570
mg/kg/day) on days 6-15 of gestation, in comparison with a
group of animals receiving Al hydroxide (57 mg Al/kg/day)
only [16]. By contrast, no signs of developmental toxicity
were observed in mice when Al hydroxide (104 mg
Al/kg/day) was given by gavage concurrently with high dos-
es of ascorbic acid (85 mg Al/kg/day) on gestation days 6-
15 [17].
A summary of the above studies is presented in Table 1.
Effects of aluminium on postnatal development
and behaviour of the offspring
The effects on reproduction, gestation, parturition and lacta-
tion of oral Al exposure (0, 13, 26 and 52 mg Al/kg/day given
as Al nitrate nonahydrate) were assessed in rats [25,26].
Male rats were treated orally for 60 days prior to mating with
mature virgin female rats treated for 14 days prior to mating
with treatment continuing throughout mating, gestation, par-
turition, and weaning of the pups. One-half of the dams in
each group were killed on gestation day 13 and the remain-
ing dams were allowed to deliver and wean their offspring.
Although no adverse effects on fertility or general reproduc-
tive parameters were noted, the survival ratios were higher in
the control group. A dose-dependent delay in the growth of
the living pups was also observed in all Al-treated groups
[25]. The growth of the offspring was also significantly de-
layed when in a subsequent experiment Al nitrate nonahy-
drate (52 mg Al/kg/day) was given orally to rats from birth
throughout lactation [26].
Yokel [80-82] reported few effects in the suckling off-
spring of rabbits whose does received subcutaneous injec-
tions of Al lactate at doses of 0.68, 2.7 or 10.8 mg Al/kg/
injection, which was attributed to a probable limited distrib-
ution of Al into milk, together with a poor gastrointestinal Al
absorption [80,83]. These studies, as well as other investi-
gations conducted on rats and mice, indicated that Al is
present in the milk of Al-exposed dams but that it would not
readily accumulate in pups during lactation [37]. By con-
trast, although in the placenta of pregnant rabbits and
mice, Al concentrations were found to be four- to five-fold
higher than those found in most fetal or maternal soft tis-
sues of rabbits and mice, accumulation in the placenta did
not apparently lessen or prevent Al accumulation in the fe-
tus [37,38]. This could indicate that the delay on postnatal
development following Al exposure is due to an Al accumu-
lation in the fetuses, rather than Al absorption from the milk
of the dam. However, a lack of remarkable Al transfer with
lactation would not necessarily indicate that elevated Al in
milk does not cause adverse effects on the offspring. Golub
and co-workers [43] showed that nursing pups of mouse
dams fed excess Al in their diet exhibit poor retention of
iron and manganese from a milk meal. However, subcuta-
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Dose
Aluminium Compound mg Al/kg/day Species Route Maternal Toxicity Embryo/Fetal Toxicity Reference
Al hydroxide 23, 46, 92 Mice PO No adverse effects No adverse effects 27
Al hydroxide 66, 132, 266 Rats PO No adverse effects No adverse effects 44
Al chloride 15, 20, 40 Rats IP Maternal deaths Embryolethality, growth 8
(at 40 mg Al/kg/day). retardation, fetal
Reduced body weight gain abnormalities, (at 20 and
40 mg Al/kg/day)
Al chloride 20, 30, 40 Mice IP No adverse effects Decreased fetal weight, 20
increased number of
resorptions
Al lactate 10, 20, 40 Mice SC No adverse effects Decreased fetal crown-rump 39
lengths (at 20 mg Al/kg/
day)
Al nitrate nonahydrate 13, 26, 52 Rats PO Reduced body weight gain Fetotoxicity including 65
and food consumption teratogenic effects
Al hydroxide + citric acid 133 Mice PO Reduced body weight gain Reduced fetal body weight, 45
(62 mg/kg/day) increase in the incidence
of skeletal variations
Al hydroxide + lactic acid 57 Mice PO Reduced body weight gain Reduced fetal body weight, 16
(570 mg/kg/day) increase in the incidence
of skeletal variations
Al hydroxide + ascorbic 104 Mice PO No adverse effects No adverse effects 17
acid (85 mg/kg/day)
Table 1. Maternal and embryofetal toxicity of aluminium compounds: A summary of various studies1
1 Data from Domingo [21]
neous administration of Al lactate (2.5-10 mg/kg/day) to
rats on gestational days 7-15 had no effect on birthweight,
mean litter size, and the day of eye and ear opening [48].
Similar findings were also reported by Muller et al. [62] and
Yokel [81].
On the other hand, a number of studies conducted in rats
and mice show that maternal oral Al exposure can alter per-
formance on a neurobehavioural test battery, specifically im-
paired negative geotaxis, and reduced forelimb and
hindlimb grip strength [9,10,32,39-42]. A markedly reduced
activity level during behavioural testing was reported in adult
rats after developmental Al exposure [15,62]. However, no
deficits in the test of delayed alterations [43], in the radial
maze [15], or in the operant light avoidance task [62] were
found in adult mice and rats exposed to Al during develop-
ment. Notwithstanding, Gonda et al. [49] reported that al-
though the learning ability of the pups of rats given 9.8
mg/kg/day of Al lactate on gestation days 7-15 was impaired
in a passive avoidance task, no effect on the acquisition of a
conditioned taste aversion was noted. In turn, Poulos et al.
[67] showed that oral Al administration to rats during preg-
nancy and lactation produced delay in the development of
the central nervous system of their pups. The relevance of
these findings for children exposed to Al still needs to be de-
termined by extending the evaluations to more complex
CNS functions, including learning, regulation of arousal and
sensory abilities [37]. The most striking results of a number
of these studies are summarized in Table 2.
Developmental effects of aluminium and stress
A number of studies in mammals have shown that during
pregnancy, maternal stress from restraint, noise, light, and
heat among others may be associated with adverse effects
on embryo/fetal development [68]. Of special concern is the
finding that interaction between maternal stress and some
chemical teratogens can enhance the developmental toxici-
ty of those chemicals.
Since Al is ubiquitous, exposure to this element is in fact
unavoidable. This means that pregnant women may be po-
tentially exposed to Al in food, drinking water, soil ingestion,
and some medications. They may also be concurrently ex-
posed to various types of stress, either at home or in the
workplace. Because both Al and maternal stress during
pregnancy have been shown to produce adverse develop-
mental effects in mammals, we investigated the develop-
mental toxicity in mice of a combined exposure to Al and
maternal stress [18,19]. The model stressor used was mater-
nal immobilization. Among the animal models to examine the
effects of maternal stress on the embryo/fetal toxicity of a
chemical, restraint has been widely used.
In a first study, the potential interaction between Al and
maternal restraint stress was assessed in mice. Four groups
of plug-positive female mice were given intraperitoneal in-
jections of AlCl3 at 37.5 and 75 mg/kg/day on days 6-15 of
gestation. Two of these groups were also subjected to re-
straint for 2 h/day during the same gestational days. Mater-
nal toxicity was significantly enhanced by restraint stress at
75 mg AlCl3/kg/day. No signs of embryo/fetal toxicity were
observed following exposure to Al, maternal restraint, or
combined Al and restraint. However, a significant decrease
in fetal body weight, as well as a significant increase in the
number of litters with morphologic defects was observed in
the group exposed to 75 mg AlCl3/kg/day plus maternal re-
straint (Table 3). These results suggest that maternal stress
exacerbates Al-induced maternal and developmental toxici-
ty only at high Al doses of the metal, which are also toxic to
the dam [18].
In a subsequent investigation, we assessed the potential
influence of maternal restraint stress and Al on the postna-
tal development and behaviour of the offspring. On days 6-
15 of gestation, two groups of pregnant mice received in-
traperitoneal injections of AlCl3 at 75 mg/kg/day. One of
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Aluminium
Compound Dose Species Route Neurodevelopmental Effects Reference
Al lactate 500, 1000 ppm Mice Diet Hindlimb paralysis, seizures and death. 39
Altered performance on a neurobehavioural
test battery (foot splay, forelimb and
hindlimb grip strengths, thermal
sensitivity)
Al lactate 0.5 and 1 mg Al/g diet Mice Diet Reduced motor activity 40
Al lactate 1 mg Al/g diet Mice Diet Reduced forelimb grasp strength, 41
impaired negative geotaxis, decreased
temperature sensitivity
Al lactate 1 mg Al/g diet Mice Diet Decreased motor activity, decreased grip 41
strength, decreased startle responsiveness
Al lactate or 100-400 mg Al/kg/day Rats PO Delay in neuromotor maturation of pups, 9,10,62
Al chloride (righting reflex, grasping reflex, negative
geotaxis, locomotor coordination),
increase in postnatal death rate, growth
retardation
Table 2. Neurodevelopmental toxicity of aluminium compounds: A summary of various studies1
1 Data from Domingo [21]
these groups was also subjected to restraint for 2 h/day
during the same days of gestation. The pups were evaluat-
ed for physical development, neuromotor maturation and
behaviour on postnatal days 22, 30 and 60. The results
showed that, although no significant effects of maternal Al
plus restraint on the behaviour of the offspring were noted,
a significant influence of maternal stress on Al-induced
postnatal developmental effects was observed [19]. This
agrees with the previous results showing that maternal
stress could enhance the Al-induced embryo/fetal toxicity
in mice [18].
Protective effects of chelators on Al-induced
maternal and developmental toxicity
Chelating agents such as desferrioxamine (DFO) and some
3-hydroxypyridin-4-ones can be effective in reducing Al
body burdens [46,47,84]. As there were no data on potential
chelation therapies to protect pregnant women, infants and
children against Al-induced maternal and/or developmental
toxicity, recently the protective activity of DFO and de-
feriprone (1,2-dimethyl-3-hydroxypyrid-4-one, L1), two effi-
cient chelators for the treatment of Al overload, on Al-
induced maternal and developmental toxic effects was eval-
uated in mice.
In a first study, Al chloride was intraperitoneally injected to
pregnant mice at 0, 60, 120 and 240 mg/kg/day on gestation
days 6-15, while DFO was administered subcutaneously at
40 mg/kg/day on days 6-18 of gestation. In a previous study
[14], we found that the non-observable adverse-effect level
(NOAEL) for developmental toxicity of parenteral DFO in
mice was 176 mg/kg/day. Significant amelioration by DFO of
Al-induced maternal toxicity was only noted at 120
mg/kg/day, while no effects were observed of DFO on fetal
body weight, the only embryo/fetal parameter significantly
affected by maternal Al exposure [1]. The unexpected lack
of Al-induced embryotoxicity found in this study could be
due to the chelating activity of DFO on Al3+ in dam tissues,
which would prevent this ion from reaching the embryo.
In a second study, a single oral dose of Al nitrate nonahy-
drate (1327 mg/kg) was given to mice on gestation day 12,
the most sensitive time for Al-induced maternal and devel-
opmental toxic effects in this species. At 2, 24, 48 and 72 hr
thereafter, deferiprone was given by gavage at 0 and 24
mg/kg. Aluminium-induced maternal toxicity was evidenced
by significant reductions in body weight gain and food con-
sumption, while developmental toxicity was evidenced by a
significant decrease in fetal weight per litter and an increase
in the total number of fetuses and litters showing bone retar-
dation. No beneficial effects of deferiprone on these adverse
effects could be observed. In contrast, a more pronounced
decrease in maternal weight gain, as well as an increase in
the number of litters with fetuses showing skeletal variations
were observed in the group given Al and deferiprone [2].
As both DFO and deferiprone failed to protect against Al-
induced maternal and developmental toxicity, we also inves-
tigated whether dietary Si could prevent the toxic effects
caused by Al in the pregnant animals. The rationale of this
study was based on clear evidence showing that oral silicon
can reduce the gastrointestinal absorption of Al and increas-
es its elimination [6,84]. The preventive mechanism appears
to involve the formation of hydroxyaluminosilicates by the ad-
sorption of silicic acid onto an Al hydroxide template [54]. On
gestation days 6-15, Al nitrate nonahydrate (398 mg/kg/day)
was given by gavage to three groups of pregnant mice, which
also received silicon in drinking water at concentrations of 0,
118 and 236 mg/l on days 7-18 of gestation. Although silicon
administration at 236 mg/l significantly reduced the percent-
age of Al-induced maternal deaths, abortions and early deliv-
eries, neither 118 nor 236 mg/l of silicon produced significant
ameliorations on Al-induced fetotoxicity [7].
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Control Restraint AlCl3 alone AlCl3 AlCl3 alone AlCl3
group alone (37.5 mg/kg) (37.5 mg/kg) (75 mg/kg) (75 mg/kg)
+ restraint + restraint
No. of Plug-Positive
Females (day 0) 12 9 11 14 14 17
Deaths 0 0 1 2 2 2
Abortions 0 0 0 4 2 7
Early Deliveries 0 0 0 0 0 0
Evaluated at Term 12 9 10 8 10 8
Resorbed Litters 0 0 0 0 0 0
No. of Litters 12 9 10 8 10 8
Body Weight at Termination (g) 54.26±5.69 51.02±3.64 51.94±1.90 49.76±4.82 51.47±2.52 51.53±3.71
Gravid Uterine Weight (g) 18.51±3.93a 18.77±3.20a 16.44±0.92ab 14.59±3.68b 14.65±2.76b 14.85±2.60b
Corrected Body Weight (g) 36.08±5.43ab 32.24±0.92b 35.18±1.19ab 36.23±5.77ab 37.03±2.62a 36.43±2.21a
Corrected Body Weight Change (g) 9.26±2.24ab 7.57±9.54b 9.44±2.14ab 10.52±4.40a 11.27±1.74a 7.44±2.09b
Fetal Body Weight (g) 1.30±0.11a 1.26±0.12ab 1.13±0.08bc 1.05±0.16cd 1.06±0.11cd 0.91±0.15d
Total Fetuses with Internal or
Skeletal Defects (Litters) 5 (4)a 7 (3)a 5 (3)a 3 (3)a 5 (3)a 31 (8)b
Table 3. Effects of restraint stress on developmental toxicity of aluminium in mice1
1Data from Colomina et al. [18]. Results are presented as means ± SD. Values in the same row not showing a common superscript (a,b,c,d) are signifi-
cantly different (p < 0.05).
Conclusions
Al is a well-known developmental toxicant following par-
enteral exposure [21,22,37]. Moreover, although no evi-
dence of embryo/fetal toxicity was observed when high dos-
es of Al hydroxide were given orally to pregnant rats and
mice, some signs of maternal toxicity and fetotoxicity were
found when Al hydroxide was given to mice concurrently
with citric or lactic acids, or when Al was administered orally
as Al nitrate, lactate, or chloride to rats and mice. Theferore,
it seems well established that oral Al exposure during preg-
nancy can cause a syndrome including growth retardation,
delayed ossification, and malformation at Al doses that also
lead to reduced maternal weight gain. The severity of these
effects is highly dependent on the chemical form of Al ad-
ministered. In turn, in the postnatal period, reduced pup
weight gain and effects on neuromotor development and be-
haviour can occur as a consequence of maternal and devel-
opmental Al exposure.
A recent review by Borak and Wise [13] attempts to mini-
mize the potential toxicity of Al during pregnancy by stating
that environmental and dietary Al exposures are unlikely to
pose risks of Al accumulation to pregnant animals or their fe-
tuses, but the weight of evidence would seem not to support
this statement [38]. In relation to this, the current review
shows a lot of evidence on Al-induced maternal and devel-
opmental toxicity in rats and mice.
On the other hand, recent attention has also focused on Al
toxicity in infants. Moreno et al. [61] reported that both,
preterm and full-term neonates are susceptible to Al accu-
mulation in tissues while receiving parenteral nutrition. In
turn, Bishop et al. [12] showed that, in preterm infants, pro-
longed intravenous feeding with solutions containing Al is
associated with impaired neurologic development. Bishop
et al. [11] had previously shown increased concentrations of
Al in the brain of a parenterally fed premature infant.
According to the results of the studies here reviewed, in-
cluding those on the enhancement of Al absorption from the
gastrointestinal tract by certain dietary constituents, the po-
tential effects of maternal stress on Al-induced maternal and
developmental toxic effects and the lack of an adequate,
safe and effective treatment to protect against these poten-
tial adverse effects, indicate the advisablility of avoiding
high-dose consumption of Al-containing compounds during
gestation and lactation. Data on human studies also suggest
this recommendation. The results of Weberg et al. [78], who
performed a small trial to assess whether antacids contain-
ing Al were safe during pregnancy, and the findings of
Gilbert-Barness et al. [35], based on data related to the
death of a 9-year-old girl, who failed to progress develop-
mentally at age 2 months, and whose mother ingested very
high amounts of Al hydroxide daily during the entire preg-
nancy, support the hypothesis that Al exposure during preg-
nancy can be a developmental hazard.
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